An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients
Authors:
Open Access
- 1 January 2005
- journal article
- review article
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 11, 17-23
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Vancomycin does not benefit persistently febrile neutropenic people with cancer: Abstracted from: Cometta A, Kern WV, De Bock R, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin–tazobactam monotherapy. Clin Infect Dis 2003;37:382–9.Cancer Treatment Reviews, 2004
- Antimicrobial therapy of unexplained fever in neutropenic patientsAnnals of Hematology, 2003
- Treatment of febrile neutropenia: what is new?Current Opinion in Infectious Diseases, 2002
- 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with CancerClinical Infectious Diseases, 2002
- Incidence of septicaemias and invasive mycoses in children undergoing treatment for solid tumoursEuropean Journal of Cancer, 2001
- Microbiological Findings in Febrile NeutropeniaArchives of Medical Research, 2000
- Fever in Immunocompromised PatientsNew England Journal of Medicine, 1999
- Nosocomial Bloodstream Infections in United States Hospitals: A Three‐Year AnalysisClinical Infectious Diseases, 1999
- Cumulative Meta-Analysis of Therapeutic Trials for Myocardial InfarctionNew England Journal of Medicine, 1992
- A Comparison of Results of Meta-analyses of Randomized Control Trials and Recommendations of Clinical ExpertsJAMA, 1992